Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label afatinib (Giotrif) in EGFR-mutant locally advanced or metastatic NSCLC
2009-017661-34Phase 3Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2013
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of afatinib in non-small cell lung cancer (NSCLC), sponsored by Boehringer Ingelheim. Primary endpoint: Safety (adverse events by CTCAE v3). Started Apr 2013; status: completed.
02
Drugs
afatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2009-017661-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-017661-34.